Core Viewpoint - The company, Baiyunshan (00874.HK), has announced a transaction involving the sale of additional underlying assets to Xingzheng Asset Management for a total purchase price of RMB 440,280,622.20, aimed at enhancing liquidity through asset securitization [1] Group 1: Transaction Details - Baiyunshan's non-wholly owned subsidiary, Guangzhou Pharmaceutical, signed a "New Underlying Asset Delivery Confirmation" with Xingzheng Asset Management based on the asset sale agreement (Phase IV) [1] - The transaction involves the sale of the fifth batch of additional underlying assets, confirming the financial terms and conditions of the deal [1] Group 2: Financial Implications - The transaction allows Guangzhou Pharmaceutical to utilize accounts receivable for asset securitization, converting receivables into more liquid cash assets [1] - The board of directors considers the terms of the transaction to be fair and reasonable, aligning with the overall interests of the group and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 茲提述本公司日期為2024年10月23日、11月28日、2025年2月28日、2025年5月28日及2025年8月 28日內容有關過往交易的公告。除非文意另有所指，否則本公告所用詞彙的涵義與上述公告內 所界定者相同。 須予披露的交易：出售應收賬款 本次交易 2. 本次交易及過往交易 於2025年11月28日，廣州醫藥與興證資管根據基礎資產買賣協議（第四期）簽訂《新增基礎資產交 割確認函》，確認向興證資管出售第五次新增基礎資產，並收到購買價款人民幣440,280,622.20 元。 上市規則的含義 本公司根據上市規則第14.07條單獨計算有關本次交易的所有適用百分比率低於5%，故本次交易 單獨並不構成本公司的須予公佈的交易，無須根據上市規則第十四章遵守任何披露規定。 然而，根據上市規則第14.22條，如一連串交易全部均於12個月內完成或屬彼此相關者，則該等交 易應合併計算，並視作一項交易處理。鑒於本次交易 ...

Core Insights - The "Family Medicine Cabinet" initiative by Beijing Evening News has been promoting scientific medication use for 14 years, aiming to enhance public health awareness and literacy [1][2] - The 2025 Family Medicine series is currently active, with plans to launch a "Family Medicine Box" program targeting various demographics through personalized medication advice [1][4] Group 1: Initiative Overview - The initiative has partnered with over 400 chain pharmacies in Beijing, including well-known brands, to engage the public in health discussions and medication inquiries [2][3] - Annual special editions are published based on industry trends and public voting, resulting in the "Top Ten Health Brands and Recommended Family Medicines" list, covering various medication categories [2] Group 2: Community Engagement - The initiative collaborates with the "Party Newspaper into Community" series to conduct health knowledge lectures and consultations in over a hundred communities in Beijing [3] - The "Family Medicine Box" program will expand its reach by providing free medicine and health education, enhancing community engagement [4] Group 3: Multi-Channel Approach - The program will utilize both online and offline channels to maximize participation and accessibility, ensuring the "Family Medicine" concept becomes ingrained in daily life [5] - Beijing Tongrentang and Dingdang Kuaiyao are key partners, emphasizing the importance of family medicine in health management, especially for vulnerable groups [6][7] Group 4: Supply Chain and Service Enhancements - Beijing Tongrentang has proactively stocked essential medications ahead of the flu season, ensuring availability and timely service [6] - Dingdang Kuaiyao has implemented a smart supply chain system to meet evolving health demands, providing 24/7 health services and consultations [7]

Core Viewpoint - The article highlights the significant response of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. to a fire incident in Hong Kong, showcasing the company's commitment to social responsibility through immediate disaster relief efforts [1] Company Response - Guangzhou Baiyunshan Pharmaceutical Group quickly mobilized resources to assist in disaster relief following the fire in Hong Kong [1] - The company, through its subsidiary Guangzhou Wanglaoji Health Industry Co., Ltd., donated cash and supplies worth 5 million Hong Kong dollars to support the affected individuals [1] Community Support - Baiyunshan expressed solidarity with the Hong Kong community, emphasizing a shared connection and commitment to overcoming challenges together [1]

Group 1 - The core project of Guanghua Pharmaceutical, "Children's Xiao Chai Hu Granules for treating pediatric gastrointestinal colds," has officially launched its Phase II clinical research in Tianjin, marking a significant step in traditional Chinese medicine for this indication [1] - This study is the first to apply the classic formula Xiao Chai Hu Decoction systematically for treating pediatric gastrointestinal colds, utilizing a randomized, double-blind, parallel-controlled modern evidence-based medical approach to explore the efficacy and safety of the treatment [1] - Currently, there are no similar products for children's Xiao Chai Hu Granules available in the market, indicating a potential gap in the market for pediatric proprietary Chinese medicine in this disease area [1] Group 2 - Guanghua Pharmaceutical has established multiple innovation platforms, including a doctoral workstation in Guangdong Province and a provincial enterprise technology center, and has applied for 22 core invention patents for its flagship product, Baiyunshan Xiao Chai Hu Granules [2] - The fingerprint detection method for Xiao Chai Hu Granules has been included in the 2025 edition of the Chinese Pharmacopoeia, showcasing the company's commitment to quality and innovation [2] - In response to a recent fire incident in Hong Kong, the company promptly mobilized resources and donated cash and materials worth 5 million HKD to support disaster relief efforts [2]

Group 1 - The final event of the "Science and Technology All Games, Shared by All" series will take place on November 30, 2025, in Guangzhou, featuring immersive experiences and interactions with world champion Liu Huaxiu [1][3] - The event will include various themed exhibition areas such as "Zero Carbon" Sports Technology Exhibition, Immersive Experience Zone, Robot Mobilization Exhibition, and Health Food Zone, showcasing cutting-edge technologies from multiple companies and institutions [2] - Previous events in the series attracted nearly a thousand participants, highlighting the successful engagement through high-tech products and interactive experiences [3] Group 2 - Local companies like Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. and China Life Insurance Co., Ltd. Guangzhou Branch will present their research achievements in health protection, travel services, and nutritional support [2] - The event aims to deepen the integration of technology and sports, showcasing the innovative vitality empowered by technology [3] - Participants can collect stamps through interactive tasks to exchange for commemorative gifts, promoting a festive atmosphere around the event [3]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced the inclusion of its subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd.'s land and fixed assets into the land reserve plan, with a total compensation amount of approximately 375.24 million yuan and an additional land transfer reward of about 73.32 million yuan, totaling approximately 448.57 million yuan [1][2]. Group 1 - The land and fixed assets of Guanghua Pharmaceutical located at No. 355, Shatai North Road, Baiyun District, Guangzhou, have been included in the land reserve plan [1][2]. - The compensation agreement was signed on November 27, 2025, with the Baiyun District People's Government, and the total compensation amount is 375,244,134 yuan [1][2]. - The compensation includes approximately 366,618,840 yuan for land included in the "Three Olds" renovation program and 8,625,294 yuan for land not included in this program [2]. Group 2 - The total compensation and land transfer reward amount to approximately 448,567,902 yuan, contingent upon meeting the "net land" standards [1][2]. - The transaction does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1][3]. - The transaction was approved by the company's Strategic Development and Investment Committee, and does not require further approval from the board or shareholders [3]. Group 3 - The land area involved in the transaction is 29,429.56 square meters, with a total building area of 10,530.35 square meters, including offices, workshops, and warehouses [6]. - The land has a clear ownership status, with no existing mortgages or legal restrictions [7]. - The land was acquired in 2002 with a usage period of 50 years, and has been depreciated for 23 years [8]. Group 4 - The compensation pricing is based on evaluations from two real estate appraisal firms, with the average land price used to determine the compensation amount [9][10]. - The compensation for the "Three Olds" portion is calculated at 50% of the market assessed land price, resulting in approximately 366,618,840 yuan [9]. - The non-"Three Olds" portion is evaluated at approximately 8,625,294 yuan based on different appraisal methods [10]. Group 5 - The agreement stipulates that the first compensation payment of 80 million yuan will be made after the land ownership is deregistered, with subsequent payments contingent on land transfer completion [13]. - The company plans to manage logistics through warehouse leasing during the transition period, ensuring no personnel displacement [15]. - The land reserve will not lead to related party transactions or competition within the industry [15].

Group 1 - Baidu's Biotech Company, Bai'ao Saitou, is set to launch its IPO on the Sci-Tech Innovation Board, aiming to raise 1.185 billion yuan for early drug development services, antibody drug research, and working capital [1] - Changchun High-tech's subsidiary received approval for its clinical trial application for GenSci142 capsules, marking the first approval under the new 30-day review channel for innovative drugs [2] - Antu Bio announced it received 18 medical device registration certificates, enhancing its product offerings and competitiveness in the market [3] Group 2 - Yidu Tech reported a revenue of 358 million yuan for the six months ending September 30, 2025, reflecting an 8.7% year-on-year growth, with a narrowed loss of 15.76 million yuan [4] - Baiyunshan's subsidiary, Guanghua Pharmaceutical, will receive a total compensation of approximately 449 million yuan for land and fixed assets included in a land reserve program, which aligns with the company's long-term development goals [5]

白云山（600332）(00874)发布公告，本公司附属子公司光华制药位于广州市白云区沙太北路355号地块 及固定资产被纳入《白云同和片区土地储备实施方案》拟收储土地范围。于2025年11月27日，光华制药 与同和街道办事处订立土地收储补偿协议。根据该协议，本次地块收储补偿金额为人民币3.75亿元，地 块达到"净地"标准等条件，可获得交地奖励约人民币7332.38万元，上述补偿及交地奖励合计约人民币 4.49亿元。 ...

Core Viewpoint - Baiyunshan (00874) announced that its subsidiary Guanghua Pharmaceutical's land and fixed assets in Guangzhou have been included in the land reserve implementation plan for the Baiyun Tonghe area, with a compensation agreement signed for land storage [1] Summary by Categories Land Acquisition - Guanghua Pharmaceutical's land located at No. 355, Shatai North Road, Baiyun District, Guangzhou, is set to be included in the land reserve plan [1] - A land storage compensation agreement was established with the Tonghe Street Office, effective until November 27, 2025 [1] Financial Implications - The total compensation amount for the land storage is approximately RMB 375 million [1] - The land will meet the "net land" standard, allowing for an additional land transfer reward of about RMB 73.32 million [1] - The combined total of compensation and land transfer reward amounts to approximately RMB 449 million [1]